SK2262001A3 - Non-peptide gnrh agents, methods and intermediates for their preparation - Google Patents

Non-peptide gnrh agents, methods and intermediates for their preparation Download PDF

Info

Publication number
SK2262001A3
SK2262001A3 SK226-2001A SK2262001A SK2262001A3 SK 2262001 A3 SK2262001 A3 SK 2262001A3 SK 2262001 A SK2262001 A SK 2262001A SK 2262001 A3 SK2262001 A3 SK 2262001A3
Authority
SK
Slovakia
Prior art keywords
substituted
compound
heterocycle
unsubstituted alkyl
aryl
Prior art date
Application number
SK226-2001A
Other languages
English (en)
Slovak (sk)
Inventor
Mark Brian Anderson
Haresh N Vazir
David Robert Luthin
Genevieve Deguzman Paderes
Ved P Pathak
Lance Christopher Christie
Yufeng Hong
Eileen Valenzuela Tompkins
Haitao Li
James Faust
Original Assignee
Agouron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agouron Pharma filed Critical Agouron Pharma
Publication of SK2262001A3 publication Critical patent/SK2262001A3/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/14—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/12—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/14—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SK226-2001A 1998-08-20 1999-08-20 Non-peptide gnrh agents, methods and intermediates for their preparation SK2262001A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9752098P 1998-08-20 1998-08-20
PCT/US1999/018790 WO2000020358A2 (en) 1998-08-20 1999-08-20 NON-PEPTIDE GnRH AGENTS, METHODS AND INTERMEDIATES FOR THEIR PREPARATION

Publications (1)

Publication Number Publication Date
SK2262001A3 true SK2262001A3 (en) 2002-12-03

Family

ID=22263796

Family Applications (1)

Application Number Title Priority Date Filing Date
SK226-2001A SK2262001A3 (en) 1998-08-20 1999-08-20 Non-peptide gnrh agents, methods and intermediates for their preparation

Country Status (33)

Country Link
EP (1) EP1105120B1 (de)
JP (1) JP2002535244A (de)
KR (1) KR20010085402A (de)
CN (1) CN1379666A (de)
AP (1) AP2001002053A0 (de)
AT (1) ATE291423T1 (de)
AU (1) AU759310B2 (de)
BG (1) BG105362A (de)
BR (1) BR9913374A (de)
CA (1) CA2341346A1 (de)
CZ (1) CZ2001523A3 (de)
DE (1) DE69924387D1 (de)
EA (1) EA200100255A1 (de)
EE (1) EE200100102A (de)
ES (1) ES2237966T3 (de)
GE (1) GEP20043315B (de)
HR (1) HRP20010206A2 (de)
HU (1) HUP0103622A3 (de)
ID (1) ID29244A (de)
IL (1) IL141396A0 (de)
IS (1) IS5846A (de)
LT (1) LT4904B (de)
LV (1) LV12732B (de)
NO (1) NO20010309L (de)
NZ (1) NZ509252A (de)
OA (1) OA11599A (de)
PL (1) PL356984A1 (de)
SI (1) SI20746A (de)
SK (1) SK2262001A3 (de)
TR (1) TR200100631T2 (de)
WO (1) WO2000020358A2 (de)
YU (1) YU13701A (de)
ZA (1) ZA200100831B (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69333894D1 (de) * 1992-04-22 2005-12-01 Ligand Pharm Inc Verbindungen mit Retinoid x rezeptorselektivität
IL145401A0 (en) * 1999-03-24 2002-06-30 Anormed Inc Chemokine receptor binding heterocyclic compounds
AR024158A1 (es) * 1999-06-01 2002-09-04 Smithkline Beecham Corp Compuestos antibacterianos
TWI243164B (en) 2001-02-13 2005-11-11 Aventis Pharma Gmbh Acylated indanyl amines and their use as pharmaceuticals
EP1401427A4 (de) * 2001-06-06 2004-12-01 Agouron Pharma Nicht-peptidische gnrh-agenzien, pharmazeutische zusammensetzungen und methoden zu ihrer verwendung sowie verfahren zu ihrer herstellung
EP2363396A1 (de) * 2001-06-11 2011-09-07 Virochem Pharma Inc. Thiophenderivate als antivirale Mittel gegen Flavivirus-Infektion
EP1434579B1 (de) 2001-10-09 2011-06-08 Amgen Inc. Imidazolderivate als entzündungshemmende mittel
GB0126292D0 (en) * 2001-11-01 2002-01-02 Smithkline Beecham Plc Compounds
JP2005170790A (ja) * 2002-01-09 2005-06-30 Ajinomoto Co Inc Ｎ−アルキルスルフォニル置換アミド誘導体
US6521395B1 (en) * 2002-01-30 2003-02-18 Eastman Kodak Company Infrared couplers for incorporating and recovering metadata
WO2003068769A1 (en) * 2002-02-12 2003-08-21 Pfizer Inc. Non-peptide compounds affecting the action of gonadotropin-releasing hormone (gnrh)
TW200304820A (en) * 2002-03-25 2003-10-16 Avanir Pharmaceuticals Use of benzimidazole analogs in the treatment of cell proliferation
JP2005538064A (ja) 2002-06-13 2005-12-15 ファイザー・インク 非ペプチドＧｎＲＨ剤、医薬組成物、およびそれらの使用方法
EP1562611B1 (de) * 2002-11-20 2006-08-02 Paradigm Therapeutics Ltd. Heterozyklische siliziumverbindungen und deren verwendung zur behandlung von krankheiten oder zuständen, die mit gonadotropin-freisetzenden hormon assoziiert sind
ZA200507112B (en) * 2003-03-31 2007-03-28 Taisho Pharmaceutical Co Ltd Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof
US20050197350A1 (en) * 2003-03-31 2005-09-08 Taisho Pharmaceutical Co., Ltd. Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof
US7427683B2 (en) * 2003-04-25 2008-09-23 Ortho-Mcneil Pharmaceutical, Inc. c-fms kinase inhibitors
MXPA05011503A (es) * 2003-04-25 2006-05-31 Johnson & Johnson Inhibidores de la c-fms cinasa.
US20050004133A1 (en) * 2003-06-05 2005-01-06 Makings Lewis R. Modulators of VR1 receptor
AU2004255913B2 (en) * 2003-07-09 2007-10-11 Takeda Pharmaceutical Company Limited Organosilicon compounds and their use
RU2303594C2 (ru) * 2003-07-09 2007-07-27 Пэредайм Терапьютикс Лтд. Кремнийорганические соединения и их применение
AU2004255912B2 (en) * 2003-07-10 2008-05-01 Paradigm Therapeutics Ltd. Silicon compounds and their use
WO2005039564A1 (en) * 2003-10-02 2005-05-06 Vertex Pharmaceuticals Incorporated Phthalimide compounds useful as protein kinase inhibitors
US20090291915A1 (en) * 2004-12-17 2009-11-26 Graham Andrew Showell Silicon Compounds and Their Use
JP5030947B2 (ja) 2005-05-13 2012-09-19 ヴァイロケム・ファーマ・インコーポレーテッド フラビウイルス感染の治療及び予防のための化合物及び方法
US8193206B2 (en) 2005-06-14 2012-06-05 Taigen Biotechnology Co., Ltd. Pyrimidine compounds
EA015890B1 (ru) 2005-06-14 2011-12-30 Тайджен Байотекнолоджи Ко. Лтд. Производные пиримидина
WO2007000582A1 (en) * 2005-06-28 2007-01-04 Takeda Cambridge Limited Heterocyclic non-peptide gnrh antagonists
US7345178B2 (en) * 2005-08-04 2008-03-18 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
US8008481B2 (en) 2006-03-31 2011-08-30 Ericsson Anna M Indazole compounds
US20080070987A1 (en) * 2006-05-12 2008-03-20 Francesc Yraola Font Meta-xylylenediamine vanadate salts
TW200916472A (en) 2007-06-20 2009-04-16 Sirtris Pharmaceuticals Inc Sirtuin modulating compounds
CA2701946A1 (en) * 2007-10-11 2009-04-16 Vertex Pharmaceuticals Incorporated Heteroaryl amides useful as inhibitors of voltage-gated sodium channels
JPWO2009057199A1 (ja) 2007-10-31 2011-03-10 財団法人乙卯研究所 レチノイドプロドラッグ化合物
AU2008355098B2 (en) 2008-04-21 2012-11-15 Gpcr Therapeutics, Inc Heterocyclic compounds
UY31984A (es) * 2008-07-16 2010-02-26 Boehringer Ingelheim Int DERIVADOS DE 1-(3,4-difluorobencil)-6-oxo-1,6-dihidropirimidin-5-carboxamidas N-sustituidas y de 2-(3,4-difluorobencil)-3-oxo-2,3-dihidro-1H-pirazol-4-carboxamidas N-sustituidas.
WO2010056847A2 (en) 2008-11-13 2010-05-20 Taigen Biotechnology Co., Ltd. Lyophilization formulation
SG10201505997TA (en) 2010-08-05 2015-09-29 Amgen Inc Benzimidazole And Azabenzimidazole Compounds That Inhibit Anaplastic Lymphoma Kinase
CN102050823A (zh) * 2010-10-27 2011-05-11 华东理工大学 新型光稳定剂-鸟嘌呤类似物的合成及表征
US9199918B2 (en) * 2011-02-15 2015-12-01 Georgetown University Small molecule inhibitors of AGBL2
WO2012155199A1 (en) 2011-05-16 2012-11-22 Bionomics Limited Amine derivatives as potassium channel blockers
WO2013014204A2 (en) 2011-07-26 2013-01-31 Sanofi 3-heteroaroylamino-propionic acid derivatives and their use as pharmaceuticals
EP2776411B1 (de) * 2011-11-07 2019-06-26 The University of Queensland Modulatoren von c3a-rezeptoren
CN104869990B (zh) * 2012-10-17 2022-12-20 艾科耐特有限公司 用于治疗眼部新生血管形成的化合物
GB201300304D0 (en) * 2013-01-08 2013-02-20 Kalvista Pharmaceuticals Ltd Benzylamine derivatives
WO2017070235A1 (en) * 2015-10-19 2017-04-27 Attenua, Inc. Antitussive compositions and methods
WO2019043217A1 (en) 2017-09-04 2019-03-07 F. Hoffmann-La Roche Ag DIHYDROBENZIMIDAZOLONES
ES2995214T3 (en) 2019-03-06 2025-02-07 C4 Therapeutics Inc Heterocyclic compounds for medical treatment

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3499002A (en) * 1968-06-20 1970-03-03 Robins Co Inc A H 1-carbamoyl-3-aroylpyrrolidines
NL6913261A (de) * 1968-09-09 1970-03-11
US3932444A (en) * 1972-04-28 1976-01-13 E. I. Du Pont De Nemours & Co. 4-Imidazolylsulfonylimidazoles
US4013647A (en) * 1976-03-23 1977-03-22 American Home Products Corporation Morpholine containing tetrazole-5-carboxamide derivatives
GB1491776A (en) * 1976-09-08 1977-11-16 Pfizer Ltd Thiadiazoles
US4076718A (en) * 1977-01-21 1978-02-28 American Home Products Corporation 2,6-Pyridinediyl-bis-tetrazol-5-carboxamides
US5236928A (en) * 1991-03-19 1993-08-17 Merck & Co., Inc. Imidazole derivatives bearing acidic functional groups at the 5-position, their compositions and methods of use as angiotensin II antagonists
EP0592512A1 (de) 1991-07-01 1994-04-20 University Technologies International Inc. (Uti) Nicht-desensibilisierende analoge von gnrh und andere biologisch aktive liganden
CA2126976A1 (en) * 1991-12-31 1993-07-08 Hisashi Takasugi Oxadiazole derivatives having acetylcholinesterase-inhibitory and muscarinic agonist activity
DE69628705T2 (de) * 1995-08-24 2004-05-13 Basf Ag Isoxazole- und Isothiazole-5-carboxamid Derivate, deren Herstellung und deren Verwendung als Herbizide
WO1997021707A1 (en) * 1995-12-14 1997-06-19 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
CA2254769A1 (en) * 1996-05-20 1997-11-27 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
US5878393A (en) * 1996-09-09 1999-03-02 Matsushita Electric Industrial Co., Ltd. High quality concatenative reading system

Also Published As

Publication number Publication date
EA200100255A1 (ru) 2002-02-28
OA11599A (en) 2004-08-23
TR200100631T2 (tr) 2002-08-21
KR20010085402A (ko) 2001-09-07
NO20010309L (no) 2001-04-11
GEP20043315B (en) 2004-02-10
SI20746A (sl) 2002-06-30
AU759310B2 (en) 2003-04-10
ZA200100831B (en) 2002-08-22
BG105362A (en) 2001-12-31
ID29244A (id) 2001-08-16
DE69924387D1 (de) 2005-04-28
WO2000020358A3 (en) 2000-11-16
HUP0103622A3 (en) 2003-01-28
ES2237966T3 (es) 2005-08-01
HUP0103622A2 (hu) 2002-04-29
EP1105120A4 (de) 2001-12-19
IS5846A (is) 2001-02-16
LV12732A (en) 2001-10-20
AP2001002053A0 (en) 2001-03-31
HRP20010206A2 (en) 2004-02-29
EP1105120A2 (de) 2001-06-13
WO2000020358A2 (en) 2000-04-13
LV12732B (en) 2002-03-20
LT4904B (lt) 2002-04-25
JP2002535244A (ja) 2002-10-22
WO2000020358B1 (en) 2001-01-04
IL141396A0 (en) 2002-03-10
PL356984A1 (en) 2004-07-12
NZ509252A (en) 2004-05-28
ATE291423T1 (de) 2005-04-15
CA2341346A1 (en) 2000-04-13
AU2470900A (en) 2000-04-26
EP1105120B1 (de) 2005-03-23
NO20010309D0 (no) 2001-01-19
YU13701A (sh) 2005-06-10
BR9913374A (pt) 2001-05-15
LT2001024A (en) 2001-11-26
EE200100102A (et) 2002-06-17
CN1379666A (zh) 2002-11-13
CZ2001523A3 (cs) 2002-05-15

Similar Documents

Publication Publication Date Title
CZ2001523A3 (cs) Nepeptidová GnRH činidla, způsob jejich přípravy a meziprodukty pro jejich výrobu
US7101878B1 (en) Non-peptide GNRH agents, methods and intermediates for their preparation
CN101932325B (zh) Ido抑制剂
EP1334972B1 (de) Nicht-peptidische Verbindungen, welche die Wirkung des Gonadotropin-freisetzenden Hormons (GnRH) beeinflussen
JP5754040B2 (ja) ＴＮＦαシグナル伝達のモジュレータ
KR20010041656A (ko) 비-펩타이드 성선자극호르몬-방출 호르몬 제제
JP2001525399A (ja) 選択的β３アドレナリン作動性作動薬
JP2026067907A (ja) 神経変性疾患及びミトコンドリア病の治療用の組成物ならびにその使用方法
US6903132B2 (en) Non-peptide GnRH agents, pharmaceutical compositions and methods for their use
US20040198799A1 (en) Methods of increasing endogenous testosterone levels
WO2010025142A1 (en) Substituted aminothiazole derivatives, pharmaceutical compositions, and methods of use
US20040010033A1 (en) Non-peptide GnRH agents, methods and intermediates for their preparation
KR20180085814A (ko) 치환된 5,6-디히드로-6-페닐벤조[f]이소퀴놀린-2-아민의 제조 방법
KR20110053434A (ko) Ａ３ 아데노신 수용체 알로스테릭 조절인자
CN104744451A (zh) 一种1-(3-氨基丙基)取代环状胺类化合物、其制备方法、药物组合物及用途
MXPA01001834A (en) NON-PEPTIDE GnRH AGENTS, METHODS AND INTERMEDIATES FOR THEIR PREPARATION
HK40086209B (en) Compositions and methods of using the same for treatment of neurodegenerative and mitochondrial disease
HK40086209A (en) Compositions and methods of using the same for treatment of neurodegenerative and mitochondrial disease
JP2005530685A (ja) 選択的鎮痛剤
CN107304180A (zh) 苯甲酰胺类衍生物、其制备方法及其在医药上的用途